<![CDATA[Genmab - Castor præsentation på ASCO 2016]]>Offentliggjort den 5. jun. 2016

Antonio Palumbo, Asher Alban Akmal Chanan-Khan, Katja Weisel, et alt. Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study. Abstract LBA4.

]]>https://dev.proinvestor.com/forum/topic/439443/genmab-castor-prsentation-p-asco-2016RSS for NodeSat, 18 Jul 2026 09:37:42 GMTSun, 05 Jun 2016 13:51:29 GMT60<![CDATA[Reply to Genmab - Castor præsentation på ASCO 2016 on Mon, 06 Jun 2016 13:09:55 GMT]]>Castorvideo.

Offentliggjort den 6. jun. 2016

Antonio Palumbo, MD, discusses the "unprecedented" results of the CASTOR Trial, a plenary, late-breaking abstract at ASCO 2016.

]]>https://dev.proinvestor.com/forum/post/9451844https://dev.proinvestor.com/forum/post/9451844Mon, 06 Jun 2016 13:09:55 GMT<![CDATA[Reply to Genmab - Castor præsentation på ASCO 2016 on Sun, 05 Jun 2016 19:45:33 GMT]]>Dagens Medicin i Norge:

http://www.dagensmedisin.no/artikler/2016/06/05/benmargskreft-studie--redusert-risiko-for-progresjon-med-daratumumab/

]]>https://dev.proinvestor.com/forum/post/9451845https://dev.proinvestor.com/forum/post/9451845Sun, 05 Jun 2016 19:45:33 GMT<![CDATA[Reply to Genmab - Castor præsentation på ASCO 2016 on Sun, 05 Jun 2016 18:46:48 GMT]]>Fra Plenary Session:

Start 2,38.

]]>https://dev.proinvestor.com/forum/post/9451841https://dev.proinvestor.com/forum/post/9451841Sun, 05 Jun 2016 18:46:48 GMT<![CDATA[Reply to Genmab - Castor præsentation på ASCO 2016 on Sun, 05 Jun 2016 15:51:21 GMT]]>Genmabs vidundermiddel leverer historisk gode data.

Link Preview Image
Genmabs vidundermiddel leverer historisk gode data

Analyse: Genmabs kræftmiddel Darzalex viser nok engang, hvorfor det meste af verden tror, at det kan blive et af verdens bedst sælgende lægemidler.

favicon

Finans (finans.dk)

]]>https://dev.proinvestor.com/forum/post/9451856https://dev.proinvestor.com/forum/post/9451856Sun, 05 Jun 2016 15:51:21 GMT<![CDATA[Reply to Genmab - Castor præsentation på ASCO 2016 on Sun, 05 Jun 2016 14:45:12 GMT]]>Genmab - ASCO 2016 - Diverse links.

http://abstracts.asco.org/176/AbstView_176_172609.html

ERROR: The request could not be satisfied

favicon

(www.asco.org)

Link Preview Image
Page Not Found

We’re sorry. The page you are looking for appears to have moved or does not exist. Check the URL or try using our search function at the top right. Alternatively, you might want to check out these top stories:

favicon

CNA (www.channelnewsasia.com)

Link Preview Image
Security Verification

favicon

(www.ft.com)

]]>https://dev.proinvestor.com/forum/post/9451837https://dev.proinvestor.com/forum/post/9451837Sun, 05 Jun 2016 14:45:12 GMT<![CDATA[Reply to Genmab - Castor præsentation på ASCO 2016 on Sun, 05 Jun 2016 14:34:16 GMT]]>Genmab - Mere fra Antonio Palumbo.

Offentliggjort den 5. jun. 2016

Antonio Palumbo, MD, chief, Myeloma Unit, Department of Oncology, Section of Hematology, University of Torino, Italy, discusses the phase III results of the CASTOR trial, which was a randomized controlled study examining the efficacy of daratumumab (Darzalex), bortezomib (Velcade), and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.

]]>https://dev.proinvestor.com/forum/post/9451838https://dev.proinvestor.com/forum/post/9451838Sun, 05 Jun 2016 14:34:16 GMT<![CDATA[Reply to Genmab - Castor præsentation på ASCO 2016 on Sun, 05 Jun 2016 14:31:09 GMT]]>Genmab - Offentliggjort den 5. jun. 2016

Dr. Sagar Lonial from the Winship Cancer Institute, talks about the multiple myeloma clinical trials and abstracts presented at the annual American Society of Clinical Oncologists (ASCO) meeting in Chicago, IL.

]]>https://dev.proinvestor.com/forum/post/9451839https://dev.proinvestor.com/forum/post/9451839Sun, 05 Jun 2016 14:31:09 GMT